Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01655719 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone in Thyroid Cancers
A Phase 2 study of Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
- 4
- Study locations
NCT01655719: Completed Phase 2 study of Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene, sponsored by University of Michigan.
NCT01655719 is a Phase 2 study of Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene that has completed, run by University of Michigan. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01655719, a Phase 2 study of Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
- 4
- Study locations
Study Summary
Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimental.
Primary Outcome
Response is measured by change in Tumor size (cm)
Conditions Studied
Interventions
- DRUG Pioglitazone
Study Locations (4)
Colorado
- University of Colorado - Aurora
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-04 |
| Est. Completion | 2017-03-31 |
| Phase | Phase 2 |
What the finished NCT01655719 record still lists
NCT01655719 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene appearing as the primary indexed condition, and to 1 intervention - of which Pioglitazone is the first listed.
NCT01655719 reports a single indexed study location in Colorado, Michigan, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01655719 about?
NCT01655719 is a clinical study titled "Pioglitazone in Thyroid Cancers". Through this trial the investigators hope to learn if a drug, Actos (pioglitazone), is useful in treating a certain kind of metastatic thyroid cancer. Actos is approved by the FDA to treat diabetes. It has not been approved by the FDA to treat cancer, so its use in this study is considered experimen...
What is the current status of trial NCT01655719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2012-04. Estimated completion is 2017-03-31.
What conditions does trial NCT01655719 study?
This clinical trial studies the following conditions: Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene.
What interventions are being tested in trial NCT01655719?
The interventions under investigation include: Pioglitazone (DRUG).
Who is sponsoring clinical trial NCT01655719?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01655719 being conducted?
This trial has 4 study locations across Colorado, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01655719's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia